Dear Sirs,

In previous reports, clinical characteristics of SARS-CoV-2 infection have been described, and risk factors for the development of acute respiratory distress syndrome (ARDS) and death have been proposed: among them, older age, comorbidities such as hypertension and diabetes mellitus, neutrophilia and markers of end-organ and coagulation impairment \[[@CR1]\].

Although mortality due to COVID-19 is mainly linked to visceral multi-organ failure, cerebral involvement might worsen the clinical picture. Up to 36% of patients with COVID-19 appear to have neurological manifestations, ranging from headache and dizziness to impaired consciousness and cerebrovascular events \[[@CR2]\]. The EEG correlates of such manifestations are still not clear.

We report a series of 18 consecutive COVID-19 patients, admitted to our Institution between March and April 2020, evaluated with basal electroencephalogram (EEG) to investigate infection-related neurologic manifestations. All patients had their COVID-19 diagnosis confirmed by means of duplo SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) on nasopharyngeal swabs, and compatible chest X-ray and/or CT scan.

Patients were divided in three groups, according to the level of EEG background activity alteration on a three-grade scale \[normal/mild (*N* = 5), moderate (*N* = 9) or severe (*N* = 4)\] derived with modifications from Amodio et al. \[[@CR3]\]. Neurological manifestations prompting EEG examination were transient loss of consciousness, seizures/spasms, delirium and coma, with different distribution in the patient groups; no subjects reported history of anosmia/ageusia.

Demographic and clinical features of patients are reported in Table [1](#Tab1){ref-type="table"}. The frequency of focal central nervous system (CNS) lesions at neuroimaging (CT and/or MRI scan) did not differ among groups. We observed generalized EEG slowing in 16/18 (88.9%) patients; an anterior (bifrontal) prevalence of slow waves was noted in 10/18 (55.6%) cases (Fig. S1), a finding observed also in metabolic encephalopathies \[[@CR4]\]. Its presence and severity correlated with the degree of EEG alteration (*p* = 0.02, linear regression model). This kind of abnormalities has been recently observed also by Helms \[[@CR5]\]. Only two patients presented with epileptiform discharges (one with operated high-grade glioma, one with coma and severe hypernatremia); no seizures were detected.Table 1Demographical data and main clinical results in patients stratified according to EEG alteration severityNormal/mild EEG alteration (*N* = 5)Moderate EEG alteration (*N* = 9)Severe EEG alteration (*N* = 4)*p* valueEstimate ± SESex: M/F4/15/42/20.60^a^--Age (years)62.4 ± 15.970.4 ± 8.864.3 ± 4.50.34^a^--Comorbidities-- Hypertension3/5 (60.0%)6/9 (66.7%)2/4 (50.0%)0.86^a^ Diabetes2/5 (40.0%)2/9 (22.2%)--0.38^a^ Obesity--1/9 (11.1%)1/4 (25.0%)0.51^a^ CKD1/5 (20.0%)1/9 (11.1%)--0.65^a^ COPD--1/9 (11.1%)1/4 (25.0%)0.51^a^ Asthma--1/9 (11.1%)1/4 (25.0%)0.51^a^ Atrial fibrillation1/5 (20.0%)2/9 (22.2%)2/4 (50.0%)0.55^a^ Other--IHD (2)Lung cancer (1)----Focal CNS lesions at neuroimaging2/5 (40.0%)PRES (1)Remote IPH (1)4/9 (44.4%)Glioblastoma (1)Brain metastasis (1)Traumatic SDH (1)Remote hemispheric ischemic lesion (1)1/4 (25.0%)Anterior pontine demyelinating les. (1)0.81^a^Anosmia/ageusia--------Disease onset-to-door (d)2.5 ± 3.05.8 ± 4.86.7 ± 2.50.30^a^--Disease onset-to-EEG (d)6.6 ± 7.613.3 ± 11.711.0 ± 9.90.56^a^--SpO~2~ at arrival (%)91 ± 486 ± 1366 ± 80.05^b^ \*--0.040 (0.019)Invasive ventilation--3/9 (33.3%)3/4 (75.0%)0.07^a^--Body temperature (°C)37.3 ± 1.536.8 ± 0.737.9 ± 0.50.49^a^Heart rate (bpm)91 ± 1291 ± 1693 ± 240.75^a^Outcome Alive, discharged2/5 (40.0%)1/9 (11.1%)--0.17^a^-- Alive, in-hospital2/5 (40.0%)4/9 (44.4%)1/4 (25.0%) Deceased1/5 (20.0%)4/9 (44.4%)3/4 (75.0%)Indication for EEGTransient LOC: 2/5Transient LOC: 3/9--0.03^a^ \*--Seizure/spasms: 2/5Seizure/spasms: 3/9--Delirium: 1/5Delirium: 1/9Delirium: 1/4--Coma: 2/9Coma: 3/4EEG featuresAnterior prevalence of diffuse slow waves Absent5/5 (100.0%)3/9 (33.3%)1/4 (25.0%)0.02^b^ \*0.56 ± 0.22 Intermittent--3/9 (33.3%)-- Continuous--3/9 (33.3%)3/4 (75.0%)Focal slowing1/5 (20.0%)5/9 (55.6%)1/4 (25.0%)0.37^a^Epileptiform discharges--1/9 (11.1%)1/4 (25.0%)0.51^a^Seizures--------Laboratory parameters WBC count (10^9^/L)9.52 ± 5.6410.79 ± 6.5917.58 ± 2.070.045^b^ \*0.071 ± 0.033 Ly count (10^9^/L)1.24 ± 0.380.92 ± 0.520.93 ± 0.570.43^b^-- Hyper/hyponatremia1/5 (20.0%)6/9 (66.7%)3/4 (75.0%)0.05^b^ \*0.82 ± 0.40 Creatinine (mg/dL)1.43 ± 0.201.52 ± 1.213.35 ± 2.070.024^b^ \*1.06 ± 0.42 CRP (mg/L)46.5 ± 19.5130.8 ± 81.7114.6 ± 101.90.14^b^-- LDH (U/L)352 ± 86397 ± 154436 ± 1740.57^b^-- CK (U/L)130 ± 74428 ± 9271827 ± 33190.39^b^-- Albumin (g/L)25.4 ± 1.926.5 ± 5.524.7 ± 4.00.82^b^-- PT ratio1.08 ± 0.091.16 ± 0.251.68 ± 0.570.031^b^ \*1.12 ± 0.47 APTT ratio1.01 ± 0.050.99 ± 0.081.51 ± 0.430.037^b^ \*1.58 ± 0.69 [d]{.smallcaps}-dimer (µg/dL)1.86 ± 0.492.15 ± 1.9812.19 ± 9.580.028^b^ \*0.064 ± 0.025Values are mean ± SD or *N* (%)*CKD* chronic kidney disease, *COPD* chronic obstructive pulmonary disease, *IHD* ischemic heart disease, *SDH* subdural hematoma, *d* days, *LOC* loss of consciousness, *WBC* white blood cells, *Ly* lymphocyte, *CRP* C-reactive protein, *LDH* lactate dehydrogenase, *CK* creatine kinase, *PRES* posterior reversible encephalopathy syndrome*, PT* prothrombin time, *APTT* activated partial prothrombin time^a^Kruskal--Wallis rank sum test^b^Univariate linear regression model of the specified parameter on the level of EEG alteration (normal, mild, moderate, severe); the estimate of effect (± SE), when significant, is shown on the right column. For CK, log transformation was used.

According to clinical protocols, only one subject in our cohort underwent lumbar puncture to rule out acute encephalitis, with normal results (cells, protein and glucose) and negative RT-PCR test for SARS-CoV-2; in addition, bacterial and virologic assays were negative. In the remaining 17 subjects, lumbar puncture was not performed, since not indicated on the basis of clinical judgement.

We visually screened vital and laboratory parameters for association with the degree of EEG alteration. Univariate linear regression models were built to evaluate the relationship between patient groups and selected parameters. Among vital parameters (including heart rate and body temperature), only oxygen saturation on room air (SpO~2~), measured at hospital admission appeared to be associated to the EEG abnormalities (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). As to laboratory parameters, a linear relationship with the severity of EEG alteration was observed for white blood cell (WBC) count, the presence of plasma sodium alterations, serum creatinine, and coagulation parameters (prothrombin time, activated partial thromboplastin time, and [d]{.smallcaps}-dimer) (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Plots of vital and laboratory parameters stratified by level of EEG background activity alteration. Only parameters with significant relationship at linear regression model (Table [1](#Tab1){ref-type="table"}) are shown. *SpO*~*2*~ oxygen saturation on room air, *WBC* white blood cells, *PT* prothrombin time, *APTT* activated partial prothrombin time

We recorded for all but three patients the antibiotic and/or antiviral drugs administered at the time of EEG. We did not observe significant effects of drug-related toxicity in our cohort. Moreover, laboratory parameters most commonly associated to drug therapies did not appear to influence EEG alteration; association with creatinine may be correlated to aggressive diuretic therapy salvage protocols.

Our findings suggest variable degrees of CNS involvement in COVID-19 patients. The presence of focal brain lesions did not appear to impact significantly on EEG background activity. Subjects with laboratory findings which have been associated to poor prognosis \[[@CR1]\] showed more frequent CNS impairment, as reflected by EEG alterations. Moreover, lower values of oxygen saturation at admission were associated with more severe EEG abnormalities, suggesting that higher levels of hypoxemia, and possibly longer periods before access to cures, may contribute to brain dysfunction.

Electroencephalogram (EEG) may therefore represent a useful tool to evaluate early cerebral involvement in COVID-19, especially in severe cases; a frequent finding in our cohort was an anterior prevalence of slow waves. We hypothesize that the main drivers of EEG alterations in these patients are metabolic and/or hypoxic encephalopathy, even if our data cannot exclude the contribution of cerebral microangiopathy, yet to be demonstrated. We believe that our data raise a warning against a delayed access to specialized cures in SARS-CoV-2 infection, in order to reduce the incidence of brain suffering.
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Below is the link to the electronic supplementary material.Fig. S1 EEG recordings in two COVID-19 patients, showing diffuse slowing with anterior prevalence (boxes). a) EEG showing moderate background activity alteration, with minimal reactivity to auditory stimulation ("stimolo acustico") in a patient with leukocytosis (17.7 × 10\^9/L), increased creatinine (5.76 mg/dL), PT (2.1) and D-dimer (16.75 µg/dL). b) Severe EEG alteration. The arrow indicates a diffuse epileptiform discharge in a patient with hypernatremia (155 mmol/L) and leukocytosis (18 × 10\^9/L) (PDF 2427 kb)
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